NCT01489176View on ClinicalTrials.gov

Regadenoson Real Time Perfusion Imaging Trial-Optison

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

April 1, 2014

Study Completion Date

December 1, 2014

Conditions
Coronary Artery DiseaseMyocardial Perfusion Abnormalities
Interventions
DRUG

Regadenoson; Optison

A one-time intravenous bolus of Regadenoson 400 mcg; continuous intravenous infusion of Optison of 2-4 mL/minute.

Trial Locations (2)

55905

Mayo Clinic, Rochester

68105

University of Nebraska Medical Center, Omaha

Sponsors

Collaborators (1)

GE Healthcare
All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

collaborator

GE Healthcare

INDUSTRY

lead

University of Nebraska

OTHER